Ascletis Pharma adjusts share capital, repurchases shares in October

Ascletis Pharma Inc. reported a decrease of 1,100,000 in issued shares (excluding treasury shares), bringing the total to 992,074,320 for the month ended October 31, 2025. Concurrently, the number of treasury shares increased by 1,100,000 to 6,884,210. This resulted in the total number of issued shares remaining unchanged at 998,958,530. The company's authorised/registered share capital remained at $700,000, with 7,000,000,000 ordinary shares each having a par value of $0.0001.

During October 2025, the company repurchased 1,100,000 ordinary shares at prices ranging from HK$9.0148 to HK$10.836, which are now held as treasury shares. Additionally, 800,000 ordinary shares repurchased for cancellation in April 2025 and 160,000 ordinary shares repurchased for cancellation in October 2025 are yet to be cancelled.

Under its Share Option Scheme approved on June 6, 2019, 240,000 options were cancelled, leaving 7,403,653 options outstanding. The 2025 Share Option Scheme, approved on February 3, 2025, maintained 5,470,175 options outstanding, with a potential to issue 33,091,225 shares upon exercise of all granted options under this scheme.